Combination of Metformin and Pioglitazone and its Effect in Treatment of Comorbid Pathology
Ескіз недоступний
Дата
2018
Назва журналу
Номер ISSN
Назва тому
Видавець
Wiadomosci Lekarskie
Анотація
Introduction: The early development and high incidence of cardiovascular lesion in patients with type 2 diabetes mellitus is one of the most serious challenges for the diabetology worldwide.
Aim: The purpose of the paper is to determine the dynamics of the insulin resistance indices in patients with type 2 diabetes mellitus concomitant with coronary heart disease in the combination therapy with metformin and pioglitazone during 3 and 6 months. Materials and Methods: 95 patients with type 2 diabetes mellitus and coronary heart disease have been treated and randomized into two groups: the comparison group (n=37), treated with metformin and sulfonylureas, and the study group (n=58), treated with metformin in combination with pioglitazone. Prior, after 3 and 6 months of treatment C-peptide was assessed and index of the insulin resistance was calculated. Results: The resulting data proved the statistically significant lowering of the markers and level of the insulin resistance under the effect of combination treatment with metformin and pioglitazone. Conclusions: The proposed variant of the combination therapy has a positive effect on the clinical course of the coronary heart disease in patients with type 2 diabetes mellitus, well tolerated by the patients and can be considered as the pathogenetic factor in the treatment of these diseases.
Опис
Ключові слова
diabetes mellitus, coronary heart disease, insulin resistance
Бібліографічний опис
Shaienko Z. O. Combination of Metformin and Pioglitazone and its Effect in Treatment of Comorbid Pathology / Z. O. Shaienko, L. Ye. Bobyreva // Wiadomości Lekarskie. – 2018. – № 2, P. ІІ. – P. 278–280.